Acer Saccharinum Pollen Alnus Rhombifolia Pollen B
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acer Saccharinum Pollen Alnus Rhombifolia Pollen B
- Multi-Tree Pollen Allergen Mixture: Preliminary Assessment — No Repurposing Predictions Available
Multi-Tree Pollen Allergen Mixture: Preliminary Assessment — No Repurposing Predictions Available
One-Sentence Summary
This product is a multi-component tree pollen allergen extract composed of 9 species (silver maple, white alder, sweet birch, shagbark hickory, white ash, American sycamore, white poplar, white oak, and cedar elm), typically used in allergen immunotherapy for IgE-mediated respiratory allergies. The TxGNN model was unable to generate repurposing predictions for this candidate, most likely because no DrugBank ID could be mapped and the multi-component mixture cannot be represented as a single node in the knowledge graph. With no clinical trials or publications identified, and no active market authorizations, a standard repurposing evaluation cannot proceed at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergen immunotherapy (tree pollen allergy desensitization) |
| Predicted New Indication | Not available — TxGNN returned no predictions |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — no predictions generated; model pipeline did not complete |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
This product is a subcutaneous or sublingual allergen immunotherapy (AIT) formulation containing whole or extracted pollen from 9 tree species: silver maple (Acer saccharinum), white alder (Alnus rhombifolia), sweet birch (Betula lenta), shagbark hickory (Carya ovata), white ash (Fraxinus americana), American sycamore (Platanus occidentalis), white poplar (Populus alba), white oak (Quercus alba), and cedar elm (Ulmus crassifolia). Products of this class are classically indicated for desensitization in patients with allergic rhinitis, allergic conjunctivitis, and/or allergic asthma triggered by tree pollen. The proposed mechanism involves repeated antigen exposure to shift the immune response from Th2-dominant IgE-mediated hypersensitivity toward immune tolerance, typically via induction of regulatory T cells and IgG4 blocking antibodies.
Currently, detailed mechanism of action data is not available in DrugBank, and no DrugBank ID was successfully mapped to this multi-component mixture. Because the TxGNN knowledge graph model requires a single, mappable drug entity as input, a multi-allergen preparation cannot be directly processed through the standard pipeline. This is a structural limitation of applying small-molecule-oriented repurposing tools to biologic immunotherapy products.
It is worth noting that the question of “repurposing” an allergen immunotherapy product is conceptually distinct from repurposing a conventional drug. Emerging research does explore broader immunological effects of AIT (e.g., cross-tolerance, reduction of new sensitizations, potential asthma prevention), but these would require specialized evidence frameworks rather than standard TxGNN output.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No authorizations are registered for this product.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This multi-component pollen allergen product could not be processed by the TxGNN pipeline due to the absence of a DrugBank ID mapping and the intrinsic incompatibility of multi-allergen biologic mixtures with knowledge-graph-based small-molecule repurposing models. Without predictions, evidence, or active regulatory registrations, there is no actionable repurposing signal to evaluate at this stage.
To proceed, the following is needed:
- Determine whether each individual pollen component should be evaluated separately, or whether a surrogate small-molecule (e.g., a benchmark AIT adjuvant) should serve as a proxy
- Identify or register DrugBank IDs for individual allergen components (e.g., Betula lenta birch allergen Bet v 1) to enable knowledge graph queries
- Clarify the regulatory pathway: confirm whether any equivalent product has US FDA approval (e.g., under BLA/NDA for standardized allergen extract), which would establish a safety and indication baseline
- Assess whether the TxGNN pipeline is the appropriate tool for allergen biologics, or whether a different computational framework (e.g., epitope-based immunoinformatics) should be used instead
- Obtain package insert or prescribing information to close the blocking safety data gap (DG001)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.